Which markers are included in the Uro-3 panel?

• A. CD44 - Atypical reactive urothelial cells- Cyto; p53 - cells with p53 mutation - nuclear; CK20 - CIS - cytoplasmic
• B. p16 - cytoplasmic; Ki-67 - nuclear; CK20 - cytoplasmic
• C. CD44; CK7; CK20
• D. CD44, CK20, Ki-67

Answer: (A)

Uro-3 is built from a trio of markers that together help distinguish reactive urothelial changes from carcinoma and specifically flag CIS. p53 status is assessed because mutations in p53 are common in urothelial carcinoma and show up as nuclear staining, signaling neoplastic change. CK20 is used for CIS detection, with a characteristic cytoplasmic staining pattern in CIS cells. CD44 adds a check on the urothelium’s behavior, helping differentiate atypical reactive changes from true neoplastic cells based on its expression pattern.

Using these three markers together increases diagnostic confidence: p53 points to malignant transformation, CK20 points to CIS, and CD44 helps separate reactive atypia from cancer, which is why this combination is included in Uro-3. Other marker sets either miss the nuclear mutation signal, the CIS pattern, or the reactive distinction, making this trio the most informative for that panel.